FDC

FDC Share Price

₹491.50 -17.55 (-3.45%)

21 Dec, 2024 22:23

SIP TrendupStart SIP in FDC

Start SIP

Performance

  • Low
  • ₹487
  • High
  • ₹515
  • 52 Week Low
  • ₹379
  • 52 Week High
  • ₹659
  • Open Price₹508
  • Previous Close₹509
  • Volume102,990

Investment Returns

  • Over 1 Month + 0.73%
  • Over 3 Month -12.85%
  • Over 6 Month + 7.21%
  • Over 1 Year + 28.43%
SIP Lightning

Smart Investing Starts Here Start SIP with FDC for Steady Growth!

Invest Now

FDC Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.3
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 8,002
  • P/B Ratio
  • 3.8
  • Average True Range
  • 15.51
  • EPS
  • 19.45
  • Dividend Yield
  • 1
  • MACD Signal
  • -2.72
  • RSI
  • 40.05
  • MFI
  • 65.32

FDC Financials

FDC Technicals

EMA & SMA

Current Price
₹491.50
-17.55 (-3.45%)
pointer
  • stock-down_img
  • Bullish Moving Average 1
  • stock-up_img
  • Bearish Moving Average 15
  • 20 Day
  • ₹508.68
  • 50 Day
  • ₹515.24
  • 100 Day
  • ₹513.43
  • 200 Day
  • ₹490.98

Resistance and Support

497.98 Pivot Speed
  • R3 537.12
  • R2 526.23
  • R1 508.87
  • S1 480.62
  • S2 469.73
  • S3 452.37

What's your outlook on FDC?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

FDC Ltd. is a leading pharmaceutical company in India, known for its flagship product, Electral. With over 300 products, FDC operates globally, exporting to 50+ countries, and is recognized for its excellence in ORS, ophthalmics, and innovative healthcare solutions.

F D C (Nse) has an operating revenue of Rs. 2,072.32 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 20% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 49 which is a POOR score indicating inconsistency in earnings, a RS Rating of 48 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

FDC Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-06 Quarterly Results & Other To consider others business matters. per share(80%)Interim Dividend
2024-08-07 Quarterly Results
2024-05-29 Audited Results
2024-02-07 Quarterly Results
2023-11-08 Quarterly Results
Date Purpose Remarks
2024-11-22 INTERIM Rs.5.00 per share(500%)First Interim Dividend

FDC F&O

FDC Shareholding Pattern

69.66%
5.79%
0.07%
2.62%
16.7%
5.16%

About FDC

  • NSE Symbol
  • FDC
  • BSE Symbol
  • 531599
  • Managing Director
  • Mr. Mohan A Chandavarkar
  • ISIN
  • INE258B01022

Similar Stocks to FDC

FDC FAQs

FDC share price is ₹491 As on 21 December, 2024 | 22:09

The Market Cap of FDC is ₹8002.1 Cr As on 21 December, 2024 | 22:09

The P/E ratio of FDC is 25.3 As on 21 December, 2024 | 22:09

The PB ratio of FDC is 3.8 As on 21 December, 2024 | 22:09

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23